
Eisai’s Kisplyx (lenvatinib) has secured recommendation from the Scottish Medicines Consortium, it has been revealed, meaning that patients on the …

The European Commission has approved the use of Eisai’s Kisplyx (lenvatinib) for the treatment of renal cell carcinoma (RCC) following …
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour

